利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

46 条记录 (耗时 0.042 秒)

    CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS
    4.
    发明申请
    CONTROLLED RELEASE COMPLEX COMPOSITION COMPRISING ANGIOTENSIN-II-RECEPTOR BLOCKERS AND HMG-COA REDUCTASE INHIBITORS 有权
    包含血管紧张素II受体阻断剂和HMG-COA还原酶抑制剂的受控释放复合组合物

    公开(公告)号：US20100074951A1

    公开(公告)日：2010-03-25

    申请号：US12513054

    申请日：2007-10-30

    申请人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Jae Woon Son

    发明人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Jae Woon Son

    IPC分类号： A61K9/20 ,  A61K9/28 ,  A61K9/42 ,  A61K9/40 ,  A61K9/36 ,  A61K31/505 ,  A61K31/47 ,  A61K31/4178 ,  A61K31/4184 ,  A61K31/404 ,  A61K31/40 ,  A61K31/366 ,  A61K9/24 ,  A61P3/10 ,  A61K31/41 ,  A61P9/00 ,  A61P11/00 ,  A61P9/12 ,  A61P3/00

    CPC分类号： A61K31/00 ,  A61K9/2077 ,  A61K9/209

    摘要： Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

    摘要翻译： 本文公开了包含血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的滞后时间延迟释放组合药物组合物及其制备方法。 该组合物是基于治疗时间来设计的，其中施用活性成分具有不同的起始时间，使得组合物的每种活性成分在体内的释放可延迟到特定的速率。 此外，该组合物对于治疗高血压和预防具有显示糖尿病，肥胖症，高脂血症，冠状动脉疾病等的代谢综合征的患者的并发症非常有效。 更具体地，组合物是药物递送系统，其被设计成使得每种药物的释放被控制到特定的速率，并且当其被吸收在体内时它可以显示出最理想的效果。

    Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors
    5.
    发明授权
    Controlled release complex composition comprising angiotensin-II-receptor blockers and HMG-CoA reductase inhibitors 有权
    包含血管紧张素-II受体阻断剂和HMG-CoA还原酶抑制剂的控制释放复合物组合物

    公开(公告)号：US08642083B2

    公开(公告)日：2014-02-04

    申请号：US12513054

    申请日：2007-10-30

    申请人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Jae Woon Son

    发明人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Jae Woon Son

    IPC分类号： A61K9/42 ,  A61K9/40 ,  A61K9/36 ,  A61K9/28 ,  A61K9/20

    CPC分类号： A61K31/00 ,  A61K9/2077 ,  A61K9/209

    摘要： Disclosed herein is a lag time delayed-release combination pharmaceutical composition comprising of an angiotensin-II-receptor blocker and an HMG-CoA reductase inhibitor, as well as a preparation method thereof. The composition is designed based on chronotherapy in which active ingredients are administered to have different onset times, such that the release of each active ingredient of the composition in body can be lag time delayed to a specific rate. Also, the composition is very effective for the treatment of hypertension and the prevention of complications in patients having metabolic syndromes which show diabetes, obesity, hyperlipidemia, coronary artery diseases and the like. More specifically, the composition is a drug delivery system designed such that the release of each drug is controlled to a specific rate, and it can show the most ideal effect, when it is absorbed in body.

    摘要翻译： 本文公开了包含血管紧张素-II-受体阻断剂和HMG-CoA还原酶抑制剂的滞后时间延迟释放组合药物组合物及其制备方法。 该组合物是基于治疗时间来设计的，其中施用活性成分具有不同的起始时间，使得组合物的每种活性成分在体内的释放可延迟到特定的速率。 此外，该组合物对于治疗高血压和预防具有显示糖尿病，肥胖症，高脂血症，冠状动脉疾病等的代谢综合征的患者的并发症非常有效。 更具体地，组合物是药物递送系统，其被设计成使得每种药物的释放被控制到特定的速率，并且当其被吸收在体内时它可以显示出最理想的效果。

    PHARMACEUTICAL PREPARATION
    8.
    发明申请
    PHARMACEUTICAL PREPARATION 审中-公开
    药物制剂

    公开(公告)号：US20110111021A1

    公开(公告)日：2011-05-12

    申请号：US12918993

    申请日：2009-02-23

    申请人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Jaw Woon Son ,  Jin Wook Kim

    发明人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Jaw Woon Son ,  Jin Wook Kim

    IPC分类号： A61K9/52 ,  A61K31/40 ,  A61K31/351 ,  A61K31/47 ,  A61K31/505 ,  A61K31/404 ,  A61K31/22 ,  A61K31/4164 ,  A61K31/5375 ,  A61K38/05 ,  A61K31/497 ,  A61K9/00 ,  A61K9/24 ,  A61K9/14 ,  A61P3/06

    CPC分类号： A61K9/209 ,  A61K9/0004 ,  A61K31/165 ,  A61K31/41

    摘要： The present invention provides a pharmaceutical preparation including a compartment containing a renin inhibitor as a pharmacologically active ingredient, and a compartment containing an HMG-CoA reductase inhibitor as a pharmacologically active ingredient, wherein one compartment is a prior-release compartment and the other compartment is a delayed-release compartment. The combination preparation of the present invention can deliver a renin inhibitor and an HMG-CoA reductase inhibitor with a time interval at a specific speed, thus reducing undesirable side-effects, improving the drug efficacy and promoting the patient compliance. Further, the pharmaceutical preparation of the present invention has pharmacological, clinical, scientific and economical advantages in the prevention or treatment of metabolic syndromes, cardiovascular diseases, renal diseases and the like, as compared with the complex drug regimens in which medicament ingredients are taken individually or simultaneously.

    摘要翻译： 本发明提供一种药物制剂，其包含含有作为药理活性成分的肾素抑制剂的隔室，以及含有作为药理活性成分的HMG-CoA还原酶抑制剂的隔室，其中一个隔室为先前释放室，另一隔室为 延迟释放室。 本发明的组合制剂可以以特定速度的时间间隔递送肾素抑制剂和HMG-CoA还原酶抑制剂，从而减少不期望的副作用，改善药物功效并促进患者依从性。 此外，与复合药物方案相比，本发明的药物制剂在预防或治疗代谢综合征，心血管疾病，肾脏疾病等方面具有药理，临床，科学和经济优势，其中药物成分单独服用 或同时。

    COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME
    10.
    发明申请
    COMBINATION PREPARATION COMPRISING INHIBITOR OF HMG-COA REDUCTASE AND ASPIRIN AND METHOD FOR MANUFACTURING THE SAME 审中-公开
    包含HMG-COA还原酶和阿司匹林的抑制剂的组合制剂及其制备方法

    公开(公告)号：US20120015032A1

    公开(公告)日：2012-01-19

    申请号：US12672630

    申请日：2008-08-08

    申请人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Sang Ouk Sun

    发明人： Sung Wuk Kim ,  Sung Soo Jun ,  Young Gwan Jo ,  Ja Seong Koo ,  Sang Ouk Sun

    IPC分类号： A61K9/28 ,  A61P9/00 ,  A61P9/10 ,  A61K31/60

    CPC分类号： A61K31/35 ,  A61K31/616 ,  A61K45/06 ,  A61K2300/00

    摘要： The present invention relates to a chronotherapeutically combined pharmaceutical formulation for preventing and treating cardiovascular diseases, which is based on the principle of administering a plurality of drugs at certain time intervals (chronotherapy). Specifically, the combined pharmaceutical formulation comprises a HMG-CoA reductase inhibitor, such as simvastatin, and aspirin. Because the combined pharmaceutical formulation was developed based on the principle of administering drugs at certain time intervals, so-called chronotherapy, it shows an excellent effect of preventing or treating cardiovascular disease compared to those of the individual administration and simultaneous administration of the single preparations. Also, it is a once-daily dosage form which increases the medication compliance of patients. Particularly, even though the content of aspirin in the combined pharmaceutical formulation is reduced, the platelet aggregation inhibitory effect of aspirin in the combined pharmaceutical formulation is equal to that of the amount of aspirin used in the prior art, while the aspirin in the combined pharmaceutical formulation shows a antihypertensive effect. In addition, the chronotherapeutically combined pharmaceutical formulation allows the two drugs, which interact with each other, to be stored for a long period of time, and the combined pharmaceutical formulation ensures the human body-safety and efficacy of the two drugs.

    摘要翻译： 本发明涉及一种用于预防和治疗心血管疾病的时间疗法组合药物制剂，其基于以特定时间间隔施用多种药物的原则（即时间疗法）。 具体地，组合的药物制剂包含HMG-CoA还原酶抑制剂，例如辛伐他汀和阿司匹林。 因为组合的药物制剂是基于以特定时间间隔给药药物的原理而开发的，即所谓的时间疗法，与单独给药和单次制剂同时给药相比，它显示了预防或治疗心血管疾病的优异效果。 此外，它是一种每日一次的剂型，其增加患者的药物依从性。 特别是，尽管组合药物制剂中阿司匹林的含量降低，但组合药物制剂中阿司匹林的血小板聚集抑制作用等于现有技术中所用阿司匹林的量，而组合药物中阿司匹林 制剂显示抗高血压作用。 另外，按时间顺序组合的药物制剂允许两种彼此相互作用的药物长时间储存​​，并且组合的药物制剂确保了两种药物的人体安全性和功效。